Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes

A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

(2016) Yui Takeshige et al.   HYPERTENSION RESEARCH

Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors

(2015) Satoshi Teramukai et al.   HYPERTENSION RESEARCH

The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy

(2015) Atsuhisa Sato   HYPERTENSION RESEARCH

Morning hypertension and night non-dipping in patients with diabetes and chronic kidney disease

(2015) Se Won Oh et al.   HYPERTENSION RESEARCH

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preface: evidence-based clinical practice guidelines for CKD—an abridged English version

(2014) Kenjiro Kimura   Clinical and Experimental Nephrology

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

(2014) Ilkka Tikkanen et al.   DIABETES CARE

Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes

(2013) Takashi Wada et al.   Clinical and Experimental Nephrology

Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study

(2013) Kazuaki Shimamoto et al.   HYPERTENSION RESEARCH

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

(2013) Vlado Perkovic et al.   KIDNEY INTERNATIONAL

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials

(2011) F. A. Holtkamp et al.   EUROPEAN HEART JOURNAL

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2010) P. L. Drury et al.   DIABETOLOGIA

Identification of an Increased Short-Term Blood Pressure Variability on Ambulatory Blood Pressure Monitoring as a Coronary Risk Factor in Diabetic Hypertensives

(2009) Motoko Ozawa et al.   CLINICAL AND EXPERIMENTAL HYPERTENSION

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes

(2009) T. Ninomiya et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Night Time Blood Pressure Variability Is a Strong Predictor for Cardiovascular Events in Patients With Type 2 Diabetes

(2008) K. Eguchi et al.   AMERICAN JOURNAL OF HYPERTENSION

Ambulatory Blood Pressure and Heart Rate in Hypertensives with Renal Failure: Comparison between Diabetic Nephropathy and Non-Diabetic Glomerulopathy

(2008) Kouichi Tamura et al.   CLINICAL AND EXPERIMENTAL HYPERTENSION

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE